Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Transdermal delivery of beneficial substances effected by a hostile biophysical environment

a biophysical environment and beneficial substance technology, applied in the direction of drug compositions, inorganic non-active ingredients, metabolic disorders, etc., can solve the problems of limited amount of pharmaceutical agents that can be delivered through simple diffusion, and limited current technology. , to achieve the effect of improving the transdermal delivery of substances and limited amount of pharmaceutical agents

Inactive Publication Date: 2009-09-03
STRATEGIC SCI & TECH
View PDF35 Cites 61 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]In some embodiments, the beneficial substances delivered transdermally may improve health, improve body function, or treat a variety of disease states.
[0009]This invention also relates, in yet another set of embodiments, to systems and methods for improving uptake of muscle improving agents, for example, by increasing local blood flow by delivering a nitric oxide donor such as L-arginine, either alone or with an adjunct such as theophylline. This invention also relates, in still another set of embodiments, to topical methods of administrating anabolic steroids, for example, steroids that exhibit unacceptable systemic toxicity. The steroids may also promote improved muscle size and function through the use of enhanced blood flow.
[0011]In yet another set of embodiments, this invention relates to the field of enhanced sexual function. In some cases, arginine and / or arginine derivatives and adjuncts may be applied to increase genital blood flow, which may increase sexual function.

Problems solved by technology

Local transdermal delivery of drugs, while desirable, is limited by current technologies.
Few pharmaceutical entities have successfully been delivered transdermally in effective dosages.
The amount of pharmaceutical agent that can be delivered through simple diffusion is also limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0055]In this example, a 57 year old woman with severe arthritis in her hands and fingers applied a cream comprising a hostile biophysical environment, along with 10% w / v ibuprofen and 12.5% w / v L-arginine, to her hands. She rubbed the cream into the skin of her hands and fingers until completely absorbed. Within 10 minutes she noticed substantial relief from the pain. Within 30 minutes the pain was completely gone. Pain relief persisted for several hours.

example 2

[0056]In this example, a 37 year old man with shoulder pain applied a cream comprising a hostile biophysical environment, along with 10% w / v ibuprofen and 12.5% w / v L-arginine, to the painful shoulder. He rubbed the cream in until it was completely absorbed. Within 30 minutes the pain was completely gone. The pain never returned.

example 3

[0057]A 54 year old woman with a severe headache in her right temple applied a cream comprising a hostile biophysical environment, 10% w / v ibuprofen, and 12.5% w / v L-arginine to the painful temple. She rubbed the cream in until completely absorbed. Within 10 minutes substantial relief of the headache was achieved. Within 20 minutes the pain was gone. The pain never returned.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and / or function, removing body fat and / or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline.

Description

[0001]This application is a continuation of U.S. patent application Ser. No. 11 / 587,323, filed Oct. 19, 2006, entitled “Transdermal Delivery of Beneficial Substances Effected by a Hostile Biophysical Environment,” by E. T. Fossel, which application is a national stage filing under 35 U.S.C. §371 of International Patent Application Serial No. PCT / US2005 / 013228, filed Apr. 19, 2005, which application claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 563,573, filed Apr. 19, 2004, entitled “Flow Assisted Transdermal Preparations of Ephedra and Ephedra Components to Avoid Adverse Effects,” by E. T. Fossel; U.S. Provisional Patent Application Ser. No. 60 / 563,575, filed Apr. 19, 2004, entitled “Flow Assisted Transdermal Delivery of Anabolic Steroids,” by E. T. Fossel; U.S. Provisional Patent Application Ser. No. 60 / 563,574, filed Apr. 19, 2004, entitled “Augmented Flow Assisted Transdermal Delivery of Anabolic Steroids,” by E. T. Fossel; U.S. Provisional Patent Applicat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/60A61K31/198A61K31/415A61K31/365A61K9/14A61K47/02A61K47/18
CPCA61K9/0014A61K47/02A61K47/183A61K31/192A61K31/519A61K47/10A61K31/522A61K9/06A61K47/18A61K47/14A61K47/26A61K31/198A61K47/06A61K31/496A61F6/04A61P1/04A61P15/00A61P15/02A61P15/10A61P17/00A61P17/02A61P17/14A61P19/00A61P19/02A61P19/08A61P21/00A61P21/02A61P25/00A61P25/06A61P29/00A61P31/00A61P31/04A61P31/12A61P31/22A61P35/00A61P43/00A61P9/00A61P9/08A61P3/10A61K9/0034
Inventor FOSSEL, ERIC THOR
Owner STRATEGIC SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products